Genetics and Genomics

Science News

MicroRNA Biophysically Modulates Cardiac Action Potential via Directly Binding to Ion Channel
Heart Disease and Stroke Statistics - 2021 Update
Genetically Determined Smoking Behavior and Risk of Nontraumatic Subarachnoid Hemorrhage
AHA names top heart disease and stroke research advances of 2020
VIDEO: The American Heart Association Response to the COVID-19 Crisis


TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
Variant Spectrum of Formin Homology 2 Domain‐Containing 3 Gene in Chinese Patients With Hypertrophic Cardiomyopathy
Sex-Related Differences in Cardiac Channelopathies
Circulatory MicroRNAs as Potential Biomarkers for Stroke Risk
Modifiable Lifestyle Factors and Risk of Stroke

Continuing Education

Registration Now Open

The GPM Council seeks to advance discovery and translation of biological insights from genetics and omics technologies to improve cardiovascular and brain health through better risk prediction, treatment and prevention for patients. Our expertise spans genetics, genomics, genomic medicine, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, and population health.

Since 1999, the BCVS Council has advanced understanding of mechanisms of basic cardiovascular regulation to support insights into cardiovascular disease and facilitate new therapies. Emphasis is on integrating molecular/cellular and physiological approaches to address problems relating to genomics, cell signaling, myocardial biology, circulatory physiology, pathophysiology, and peripheral vascular disease.

The ATVB Council focuses on arteriosclerosis, thrombosis and vascular biology. The council advances research, addresses prevention, improves diagnosis and treatment, and works actively with other organizations. It shares reliable information through its annual conference, awards and lectures, and in the AHA’s journal, Arteriosclerosis, Thrombosis, and Vascular Biology.

Results: ORION-9 with Frederick Raal, PhD

Derick Raal, PhD, principal Investigator of the ORION-9 trial provides a brief overview of the results and their significance for patients with familial hypercholesterolemia. Dr. Raal is on the faculty of Health Sciences at the University of the Witwatersrand in Johannesburg, South Africa.

American Heart Association Professional Members

Enjoy instant benefits!

  • Free Online Access to AHA Scientific Journals
  • Affiliate with our 16 Scientific Councils
  • Discounts on Scientific Conference Registration and Online Courses